Last10K.com

Oncotelic Therapeutics, Inc. (OTLC) SEC Filing 8-K Material Event for the period ending Monday, January 31, 2022

Oncotelic Therapeutics, Inc.

HISTORY TOOLS
CIK: 908259 Ticker: OTLC

View differences made from one to another to evaluate Oncotelic Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncotelic Therapeutics, Inc..

Continue

Assess how Oncotelic Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncotelic Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover

Material Contracts, Statements, Certifications & more

Oncotelic Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract
Exhibit 10.2: Material Contract
Ticker: OTLC
CIK: 908259
Form Type: 8-K Corporate News
Accession Number: 0001493152-22-002955
Submitted to the SEC: Wed Feb 02 2022 9:00:12 AM EST
Accepted by the SEC: Wed Feb 02 2022
Period: Monday, January 31, 2022
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. New Agreement
  3. New Financial Obligation
  4. Unregistered Sales

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/otlc/0001493152-22-002955.htm